Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PASG

Passage Bio Inc

4.41

Jul 13 • 11:12AM ET -0.16 (-3.50%)

Healthcare Biotechnology USA Nano NASD

Peers: AEON BCTX CLRB CRIS CTXR LGVN LPCN QNCX TPST TRAW

| Held by: VTI VXF DCOR DFAC

Index	-
Market Cap	14.17M
Enterprise Value	-13.42M
Income	-37.68M
Sales	0.00M
Book/sh	3.66
Cash/sh	10.38
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	24
IPO	Feb 28, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.20
P/C	0.42
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.73
Current Ratio	1.73
Debt/Eq	0.49
LT Debt/Eq	0.39
Option/Short	No / Yes

EPS (ttm)	-11.84
EPS next Y	-9.70
EPS next Q	-2.65
EPS this Y	27.27%
EPS next Y	7.08%
EPS next 5Y	14.82%
EPS past 3/5Y	34.05% 24.41%
Sales past 3/5Y	- -
EPS Y/Y TTM	42.29%
Sales Y/Y TTM	-
EPS Q/Q	52.47%
Sales Q/Q	-
Earnings	May 19
EPS/Sales Surpr.	5.69% -

Insider Own	7.74%
Insider Trans	25.21%
Inst Own	56.96%
Inst Trans	17.30%
ROA	-61.53%
ROE	-128.90%
ROIC	-230.32%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-13.26%
SMA50	-14.53%
SMA200	-46.51%
Trades

Shs Outstand	3.21M
Shs Float	2.96M
Short Float	3.86%
Short Ratio	1.01
Short Interest	0.11M
52W High	20.00 -77.95%
52W Low	3.29 34.04%
Volatility	6.71% 10.91%
ATR (14)	0.48
RSI (14)	38.78
Beta	1.43
Rel Volume	0.83
Avg Volume	112.87K
Volume	28,067

Perf Week	-6.17%
Perf Month	-14.04%
Perf Quarter	-55.41%
Perf Half Y	-75.94%
Perf YTD	-62.63%
Perf Year	-45.00%
Perf 3Y	-78.17%
Perf 5Y	-98.28%
Perf 10Y	-
Recom	2.33
Target Price	15.50
Prev Close	4.57
Price	4.41
Change	-3.50%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-10-26	Downgrade	Guggenheim	Buy → Neutral
Apr-21-26	Downgrade	Wedbush	Outperform → Neutral	$8
Apr-21-26	Downgrade	TD Cowen	Buy → Hold
Apr-21-26	Downgrade	Chardan Capital Markets	Buy → Neutral	$7
Mar-31-26	Initiated	Oppenheimer	Outperform	$30
Feb-10-26	Resumed	Chardan Capital Markets	Buy	$21
Nov-29-24	Resumed	Wedbush	Outperform	$3 → $4
Sep-03-24	Initiated	Rodman & Renshaw	Buy	$7
Mar-08-22	Downgrade	JP Morgan	Overweight → Neutral
Jan-19-22	Downgrade	Goldman	Buy → Neutral	$29 → $6
Jul-01-21	Initiated	Raymond James	Outperform	$29
Jun-15-21	Initiated	BTIG Research	Buy	$25
Mar-04-21	Upgrade	Goldman	Neutral → Buy	$28 → $30
Feb-04-21	Initiated	Guggenheim	Buy	$25
Jan-25-21	Initiated	Wedbush	Outperform	$26
Jan-04-21	Upgrade	JP Morgan	Neutral → Overweight	$25 → $35
Dec-11-20	Initiated	Citigroup	Neutral	$28
Aug-14-20	Downgrade	JP Morgan	Overweight → Neutral	$25
Jun-25-20	Downgrade	Goldman	Buy → Neutral	$28
Mar-25-20	Initiated	Chardan Capital Markets	Buy	$30

Show Previous Ratings

Jun-25-26 06:55AM	Remix to go public in reverse merger with once high-flying Passage Bio (BioPharma Dive) -26.36%
Jun-24-26 09:43PM	SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today (Stocktwits)
06:47PM	PASG Stock Slumps 16% After-Hours Whats Driving The Selloff? (Stocktwits)
04:05PM	Passage Bio and Remix Therapeutics Announce Merger Agreement (GlobeNewswire)
Apr-21-26 10:03AM	Intel upgraded, Reddit initiated: Wall Street's top analyst calls (The Fly)
07:00AM	Loading…
Apr-20-26 07:00AM	Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates (GlobeNewswire) -46.44%
Mar-03-26 07:00AM	Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -8.88%
Feb-19-26 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-10-25 04:15PM	Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire) +6.68% +14.84%
Nov-05-25 07:00AM	Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Oct-14-25 07:00AM	Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-01-25 09:55AM	Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet (Zacks)
Aug-28-25 07:00AM	Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-15-25 09:55AM	Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade (Zacks) -8.43%
09:25AM	Passage Bio price target lowered to $67 from $260 at Canaccord (TipRanks)
07:00AM	Loading…
Aug-12-25 07:00AM	Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Jul-10-25 07:00AM	Passage Bio Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -9.86%
Jun-23-25 07:00AM	Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update (GlobeNewswire) -14.37%
May-13-25 07:00AM	Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-07-25 12:00PM	Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-04-25 07:00AM	Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -11.37%
Feb-26-25 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-10-25 07:00AM	Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates (GlobeNewswire)
Nov-30-24 06:55AM	Passage Bio assumed with an Outperform at Wedbush (TipRanks)
Nov-14-24 07:29AM	Passage Bio Achieves Milestones in Gene Therapy Trials (TipRanks)
Nov-13-24 07:00AM	Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -12.87%
Nov-06-24 07:00AM	Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
Oct-24-24 07:00AM	Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference (GlobeNewswire) +11.40%
Sep-23-24 09:36PM	Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc (GuruFocus.com) -5.11%
07:00AM	Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
01:25AM	Loading…
Sep-19-24 01:25AM	Orbimed Advisors LLC Reduces Stake in Passage Bio Inc (GuruFocus.com)
Sep-16-24 07:00AM	Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024) (GlobeNewswire) -9.45%
Sep-10-24 07:52AM	Passage Bio Welcomes Tom Kassberg to Board of Directors (GlobeNewswire) +6.06%
Aug-30-24 07:00AM	Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.96%
Aug-08-24 07:00AM	Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -5.22%
Aug-06-24 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-01-24 12:30PM	Jim Wilson, prominent gene therapy researcher, to depart UPenn (BioPharma Dive) +6.63%
07:00AM	Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration (GlobeNewswire)
Jul-25-24 07:13AM	Passage Bio targets FDA to greenlight ALS gene therapy trial (Clinical Trials Arena) +6.23%
Jul-16-24 07:43AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients (GlobeNewswire)
Jun-18-24 09:35AM	Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.45%
Jun-05-24 07:30AM	Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-21-24 08:00AM	Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award (GlobeNewswire)
May-16-24 12:00PM	All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy (Zacks)
May-14-24 01:54PM	PASG Stock Earnings: Passage Bio Beats EPS for Q1 2024 (InvestorPlace) -10.47%
07:00AM	Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Apr-22-24 07:00AM	Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Mar-07-24 12:00PM	Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know (Zacks) -6.43%
Mar-06-24 01:52PM	PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023 (InvestorPlace)
Mar-05-24 07:00AM	Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program (GlobeNewswire)
Mar-04-24 07:00AM	Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Feb-27-24 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.12%
Feb-01-24 07:09PM	7 Analyst-Backed Stocks With Promising 10-Bagger Potential (InvestorPlace) +5.13%
Jan-31-24 07:30AM	Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-25-23 10:14PM	7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight (InvestorPlace)
Dec-20-23 07:00AM	Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities (GlobeNewswire) +7.35%
Nov-17-23 04:30PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-13-23 07:00AM	Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Oct-30-23 07:00AM	Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference (GlobeNewswire) +6.91%
Oct-20-23 04:30PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-25-23 07:00AM	Passage Bio to Present at Chardans 7th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-11-23 10:04AM	Lab Notes: Almac Group starts work on $65M Montco expansion expected to create 355 jobs (American City Business Journals)
Aug-07-23 07:15AM	Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -5.11%
07:00AM	Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study (GlobeNewswire)
Aug-01-23 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-31-23 07:00AM	Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors (GlobeNewswire)
Jul-24-23 12:37PM	Passage Bio reduces staff by 26% in latest round of job cuts (American City Business Journals) -5.31%
Jul-06-23 11:17AM	12 Best Nano Cap Stocks To Buy Now (Insider Monkey)
Jun-05-23 07:00AM	Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
May-11-23 07:00AM	Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
May-04-23 07:00AM	Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award (GlobeNewswire) +5.91%
Apr-21-23 04:01PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-17-23 07:00AM	Passage Bio to Present at Chardans 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Mar-29-23 09:02AM	Is Passage Bio (NASDAQ:PASG) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-27-23 07:00AM	Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (GlobeNewswire)
Mar-08-23 07:14AM	Passage Bio, Inc. (NASDAQ:PASG) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 12:42AM	Q4 2022 Passage Bio Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-06-23 07:00AM	Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-01-23 07:00AM	Passage Bio Seeks Pennsylvania College Student Candidates for Second Annual Tachi Yamada Scholarship Program (GlobeNewswire)
Feb-28-23 07:00AM	Passage Bio to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-27-23 07:00AM	Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023 (GlobeNewswire) +7.69%
Feb-24-23 07:00AM	Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium 2023 (GlobeNewswire) -7.87%
Feb-20-23 05:59PM	'We've turned the page': CEO says Passage Bio is building momentum after turbulent 2022 (American City Business Journals)
Feb-15-23 07:00AM	Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium 2023 (GlobeNewswire)
Jan-20-23 04:01PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-23 07:39AM	After losing 67% in the past year, Passage Bio, Inc. (NASDAQ:PASG) institutional owners must be relieved by the recent gain (Simply Wall St.)
Dec-14-22 12:13PM	Passage Bio Stock Jumps After Gene Therapy Study In Lysosomal Storage Disorder (Benzinga) +9.65%
07:00AM	Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study (GlobeNewswire)
Nov-21-22 05:24AM	Estimating The Fair Value Of Passage Bio, Inc. (NASDAQ:PASG) (Simply Wall St.)
Nov-10-22 07:00AM	Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +10.83%
Nov-08-22 07:00AM	Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day (GlobeNewswire)
Nov-03-22 07:30AM	Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022 (GlobeNewswire)
Oct-14-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.88%
Oct-11-22 12:25PM	Here's Why Passage Bio (NASDAQ:PASG) Must Use Its Cash Wisely (Simply Wall St.)
Oct-10-22 07:00AM	Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer (GlobeNewswire)
Sep-26-22 07:00AM	Passage Bio to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-19-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-11-22 07:00AM	Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations (GlobeNewswire)
Aug-05-22 07:00AM	Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)

Passage Bio, Inc. operates as a genetic medicines company. It focuses on development of therapies for central nervous system disorders. The company was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Ph.D.Dr. William Chou M.D.

Senior VPMs. Kathleen Borthwick

Chief Business OfficerMr. Stuart M. Henderson

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynx1 Capital Management LP	10% Owner	Jun 25 '26	Buy	4.12	50,055	206,101	673,759	Jun 29 04:30 PM
Chou William	PRESIDENT AND CEO	Jan 08 '26	Sale	18.44	4,076	75,159	6,524	Jan 12 04:03 PM
Borthwick Kathleen	CFO	Jan 08 '26	Sale	18.44	2,062	38,022	5,402	Jan 12 04:03 PM
Chou William	Officer	Jan 09 '26	Proposed Sale	18.43	4,076	75,120		Jan 09 04:03 PM
Lynx1 Capital Management LP	10% Owner	Sep 12 '25	Buy	6.99	19,783	138,299	611,804	Sep 15 08:05 PM
Lynx1 Capital Management LP	10% Owner	Sep 15 '25	Buy	6.99	11,900	83,175	623,704	Sep 15 08:05 PM
Lynx1 Capital Management LP	10% Owner	Sep 11 '25	Buy	6.96	325	2,261	592,021	Sep 15 08:05 PM
Lynx1 Capital Management LP	10% Owner	Jul 24 '25	Buy	5.71	66,423	379,455	591,696	Jul 24 06:12 PM
Lynx1 Capital Management LP	10% Owner	Jul 23 '25	Buy	5.74	49,302	283,033	525,273	Jul 24 06:12 PM
Lynx1 Capital Management LP	10% Owner	Jul 22 '25	Buy	5.44	13,123	71,338	475,971	Jul 24 06:12 PM
OrbiMed Private Investments VI	Stockholder	Jul 21 '25	Proposed Sale	5.56	132,645	737,506		Jul 21 05:33 PM
OrbiMed Private Investments VI	Stockholder	Jul 15 '25	Proposed Sale	6.79	53,293	361,859		Jul 15 08:17 PM

Open in Screener

KRRO

Korro Bio Inc

13.79

Jul 13 • 11:12AM ET -0.77 (-5.29%)

Healthcare Biotechnology USA Micro NASD

Peers: MGNX ABOS CAMP CNTX CRBP ELTX ENLV RNA SABS TENX

| Held by: IWM VTI IWN VXF LFSC IWO IWC VTWO VHT AVSC

Index	RUT
Market Cap	198.88M
Enterprise Value	126.79M
Income	-113.50M
Sales	3.84M
Book/sh	8.29
Cash/sh	7.97
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	58
IPO	Oct 03, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	51.79
P/B	1.66
P/C	1.73
P/FCF	-
EV/EBITDA	-
EV/Sales	33.02
Quick Ratio	8.13
Current Ratio	8.13
Debt/Eq	0.36
LT Debt/Eq	0.34
Option/Short	Yes / Yes

EPS (ttm)	-11.68
EPS next Y	-5.39
EPS next Q	-1.34
EPS this Y	56.56%
EPS next Y	0.59%
EPS next 5Y	25.06%
EPS past 3/5Y	62.00% 21.21%
Sales past 3/5Y	- -29.61%
EPS Y/Y TTM	-23.75%
Sales Y/Y TTM	-20.31%
EPS Q/Q	32.11%
Sales Q/Q	-100.00%
Earnings	May 07 BMO
EPS/Sales Surpr.	2.13% -100.00%

Insider Own	30.14%
Insider Trans	55.33%
Inst Own	59.00%
Inst Trans	28.71%
ROA	-58.83%
ROE	-87.78%
ROIC	-71.06%
Gross Margin	10.75%
Oper. Margin	-2154.03%
Profit Margin	-2954.14%
SMA20	4.40%
SMA50	12.17%
SMA200	-15.39%
Trades

Shs Outstand	14.42M
Shs Float	9.22M
Short Float	18.49%
Short Ratio	9.66
Short Interest	1.71M
52W High	55.89 -75.33%
52W Low	5.20 164.97%
Volatility	9.50% 10.48%
ATR (14)	1.18
RSI (14)	55.23
Beta	3.02
Rel Volume	1.10
Avg Volume	176.42K
Volume	57,790

Perf Week	-1.92%
Perf Month	30.22%
Perf Quarter	8.75%
Perf Half Y	50.71%
Perf YTD	72.16%
Perf Year	8.50%
Perf 3Y	-31.05%
Perf 5Y	-96.80%
Perf 10Y	-
Recom	1.25
Target Price	19.82
Prev Close	14.56
Price	13.79
Change	-5.29%

Date	Action	Analyst	Rating Change	Price Target Change
May-18-26	Initiated	Citigroup	Buy	$21
Mar-13-26	Upgrade	Raymond James	Mkt Perform → Outperform	$23
Feb-17-26	Upgrade	William Blair	Mkt Perform → Outperform
Jan-29-26	Upgrade	Piper Sandler	Neutral → Overweight	$30
Jan-29-26	Upgrade	H.C. Wainwright	Neutral → Buy	$20
Jan-29-26	Upgrade	Chardan Capital Markets	Neutral → Buy	$15
Jan-28-26	Upgrade	Oppenheimer	Perform → Outperform	$22
Jan-28-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$21
Nov-13-25	Downgrade	William Blair	Outperform → Mkt Perform
Nov-13-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$8
Nov-13-25	Downgrade	Raymond James	Strong Buy → Mkt Perform
Nov-13-25	Downgrade	Piper Sandler	Overweight → Neutral	$11
Nov-13-25	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-25	Downgrade	Chardan Capital Markets	Buy → Neutral	$7
Nov-13-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$74
Apr-16-25	Initiated	Chardan Capital Markets	Buy	$25
Jan-10-25	Initiated	Oppenheimer	Outperform	$155
Oct-21-24	Initiated	Raymond James	Strong Buy	$153
Aug-14-24	Initiated	William Blair	Outperform	$180

Show Previous Ratings

Jul-10-26 04:05PM	Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.29%
May-27-26 07:00AM	Korro to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire) +11.60%
May-19-26 07:00AM	Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -8.22%
May-15-26 04:05PM	Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.12%
May-07-26 07:00AM	Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
04:05PM	Loading…
May-05-26 04:05PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.96%
Apr-16-26 07:30AM	Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences (GlobeNewswire)
Apr-10-26 04:05PM	Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.97%
Mar-12-26 04:05PM	Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +11.30%
Mar-10-26 06:09AM	United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains? (Zacks) -6.67%
Mar-09-26 07:30AM	Korro Announces Oversubscribed $85 Million Private Placement (GlobeNewswire) +10.02%
Feb-26-26 12:15PM	Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates (Zacks)
Feb-25-26 04:05PM	Korro to Present at the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-02-26 09:53AM	H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO) (Insider Monkey)
Jan-30-26 07:35AM	Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength? (Zacks)
03:08AM	Loading…
03:08AM	Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE (MarketBeat)
Jan-29-26 09:35AM	First Solar downgraded, Fortinet upgraded: Wall Street's top analyst calls (The Fly) +13.86%
Jan-20-26 08:00AM	Korro to Host Virtual Analyst Day on January 27, 2026 (GlobeNewswire)
Jan-08-26 08:00AM	Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.77%
Nov-13-25 09:45AM	Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls (The Fly) -79.31%
09:37AM	Korro Bio Plummets To A Record Low On A Big Setback In RNA-Editing (Investor's Business Daily)
Nov-12-25 05:59PM	This biotech is halting its work with Novo Nordisk and laying off more people (MarketWatch)
05:40PM	Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs (GlobeNewswire)
Sep-02-25 04:30PM	Korro to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire) +17.25%
Aug-12-25 07:00AM	Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +6.25%
Jul-21-25 08:00AM	Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 (GlobeNewswire)
May-14-25 04:05PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.26%
May-09-25 10:31AM	Korro Bio price target lowered to $53 from $130 at H.C. Wainwright (TipRanks)
May-07-25 04:30PM	Korro Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.85% +10.55%
07:30AM	Loading…
Apr-01-25 07:30AM	Korro Appoints Biotech Industry Veteran, Loic Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire) -8.39%
07:30AM	Korro Appoints Biotech Industry Veteran, Lo c Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-28-25 06:18PM	Korro Bio: Promising Early Stage RNA Editing Company (Seeking Alpha) -5.11%
Mar-18-25 07:00AM	Korro Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-17-25 07:26AM	FDA grants orphan drug status for Korro Bio's AATD therapy (Pharmaceutical Business Review)
Mar-14-25 08:00AM	KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Feb-26-25 08:00AM	Korro to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-13-25 08:00AM	Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update (GlobeNewswire) +8.20%
Jan-07-25 08:00AM	Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.23%
Dec-10-24 08:00AM	CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors (GlobeNewswire)
Nov-21-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.70%
07:30AM	Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Nov-14-24 08:00AM	Korro to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -9.65%
Nov-12-24 04:05PM	Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -11.37% -15.55%
Nov-04-24 07:25AM	Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board (GlobeNewswire)
Oct-21-24 04:15PM	Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. (Investor's Business Daily) -5.22% -7.70%
Oct-16-24 04:20PM	Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed. (Investor's Business Daily) +93.66%
Sep-30-24 08:00AM	Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society (GlobeNewswire)
Sep-16-24 08:00AM	Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates (GlobeNewswire)
Sep-10-24 08:00AM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-28-24 08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-27-24 08:00AM	Korro to Participate in Upcoming September Investor and Scientific Conferences (GlobeNewswire)
Aug-13-24 04:01PM	Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +9.21%
Jul-01-24 08:00AM	Korro Joins the Russell 2000 , Russell 3000 , and Russell Microcap Indexes (GlobeNewswire)
Jun-25-24 12:53PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q4 2023 (InvestorPlace)
May-30-24 04:01PM	Korro to Participate in Upcoming June Investor and Scientific Conferences (GlobeNewswire)
May-20-24 02:30PM	Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference (GlobeNewswire)
May-14-24 10:55PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024 (InvestorPlace) +5.43%
04:01PM	Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-18-24 08:30AM	Korro Announces $70 Million Private Placement (GlobeNewswire)
Apr-01-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.90%
Mar-26-24 04:01PM	Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +18.43%
Feb-27-24 09:55AM	Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade (Zacks) -6.08%
08:00AM	Korro to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 09:55AM	Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect? (Zacks)
Jan-18-24 08:00AM	Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio (GlobeNewswire) -5.98%
Jan-04-24 08:00AM	Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-23 08:00AM	Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -14.67%
Nov-28-23 08:00AM	Korro Bio Appoints Dr. Rachel Meyers to Board of Directors (GlobeNewswire) +6.45%
Nov-03-23 03:31PM	UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire) +5.94%
12:19PM	Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire)
Aug-10-23 04:01PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results (Business Wire)
Jul-17-23 11:59AM	Frequency (FREQ) Up 77% on Merger Deal With Korro Bio (Zacks) -12.66%
Jul-14-23 11:22AM	Why Are Frequency Therapeutics Shares Surging Today (Benzinga) +77.47%
06:30AM	Korro Bio and Frequency Therapeutics Announce Merger Agreement (Business Wire)
May-12-23 04:01PM	Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results (Business Wire) -5.17%
Mar-10-23 07:30AM	Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-27-23 07:30AM	Frequency Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire) +5.40%
Feb-13-23 01:55PM	Hearing loss startup to cut more than half of staff in wake of trial failure (American City Business Journals) -80.54%
11:17AM	Frequency Therapeutics' Lead Hearing Loss Program Flunks, Shifts Focus To Multiple Sclerosis, Shares Plunge (Benzinga)
08:05AM	Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire)
Dec-19-22 07:30AM	Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program (Business Wire)
Dec-15-22 07:30AM	Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Companys Second Therapeutic Candidate for Sensorineural Hearing Loss (Business Wire)
Nov-17-22 07:30AM	Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results (Business Wire) -10.05%
Nov-08-22 04:05PM	Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results (Business Wire) -9.51%
Oct-12-22 07:30AM	Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire) +7.47%
Aug-30-22 07:30AM	Frequency Therapeutics to Participate in September Investor and Medical Conferences (Business Wire)
Aug-09-22 04:05PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results (Business Wire) -11.11% +9.00%
Jun-24-22 09:03AM	Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week (Simply Wall St.) -7.59%
May-25-22 12:00PM	Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-18-22 07:30AM	Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference (Business Wire) -9.02%
May-04-22 04:30PM	Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results (Business Wire)
Apr-22-22 07:30AM	Frequency Therapeutics to Participate in B. Riley Securities Neuro & Ophthalmology Investor Conference (Business Wire)
Apr-08-22 05:00PM	Frequency Exchange Corp. Virtually Closes the Market (PR Newswire) -8.82%
Mar-15-22 07:30AM	Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) +15.29%
Mar-10-22 06:35PM	Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates (Zacks) -13.70%
Feb-28-22 07:30AM	Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences (Business Wire)
Jan-14-22 05:43AM	One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous year (Simply Wall St.)
Jan-04-22 07:30AM	Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc (GuruFocus.com) +5.28%

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Ph.D.Dr. Ram Aiyar MBA

MBADr. Jean-Francois Formela M.D.

Chief Scientific OfficerDr. Loic Vincent Ph.D.

Pharm.D.Dr. Jeffrey M. Cerio J.D.

Co-Founder & AdvisorDr. Andrew Fraley Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FORMELA JEAN FRANCOIS	Director	Jul 02 '26	Sale	14.03	100,700	1,412,821	154,811	Jul 07 06:04 PM
FORMELA JEAN FRANCOIS	Director	Jul 06 '26	Sale	13.96	9,323	130,149	146,305	Jul 07 06:04 PM
Atlas Venture Fund XI, L.P.	Shareholder	Jul 06 '26	Proposed Sale	14.00	817	11,438		Jul 06 05:15 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 06 '26	Proposed Sale	14.00	8,506	119,084		Jul 06 05:15 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 02 '26	Proposed Sale	13.65	14,745	201,269		Jul 02 04:41 PM
Atlas Venture Fund XI, L.P.	Shareholder	Jul 02 '26	Proposed Sale	13.65	85,955	1,173,286		Jul 02 04:41 PM
FORMELA JEAN FRANCOIS	Director	Jun 23 '26	Sale	14.25	119,005	1,695,821	176,649	Jun 24 08:09 PM
FORMELA JEAN FRANCOIS	Director	Jun 24 '26	Sale	14.61	48,438	707,491	169,556	Jun 24 08:09 PM
FORMELA JEAN FRANCOIS	Director	Jun 22 '26	Sale	13.95	3,962	55,270	194,075	Jun 24 08:09 PM
Atlas Venture Fund XI, L.P.	Shareholder	Jun 24 '26	Proposed Sale	13.71	41,345	566,840		Jun 24 05:50 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 24 '26	Proposed Sale	13.71	7,093	97,245		Jun 24 05:50 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 23 '26	Proposed Sale	13.90	17,426	242,221		Jun 23 06:12 PM
Atlas Venture Fund XI, L.P.	Shareholder	Jun 23 '26	Proposed Sale	13.90	101,579	1,411,948		Jun 23 06:12 PM
Atlas Venture Fund XI, L.P.	Shareholder	Jun 22 '26	Proposed Sale	12.99	21,339	277,194		Jun 22 05:32 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 22 '26	Proposed Sale	12.99	3,661	47,556		Jun 22 05:30 PM
Chappell Todd	Chief Operating Officer	Jun 16 '26	Sale	10.83	3,168	34,309	16,964	Jun 17 04:14 PM
Vincent Loic A	Chief Scientific Officer	Jun 16 '26	Sale	10.83	3,418	37,017	18,297	Jun 17 04:11 PM
Cerio Jeffrey	General Counsel	Jun 16 '26	Sale	10.83	6,609	71,575	35,293	Jun 17 04:08 PM
Dolan Oliver	Senior Vice President, Finance	Jun 16 '26	Sale	10.83	3,383	36,638	18,099	Jun 17 04:05 PM
Vincent Loic A	Officer	Jun 16 '26	Proposed Sale	10.83	3,418	37,017		Jun 16 04:48 PM
Cerio Jeffrey	Officer	Jun 16 '26	Proposed Sale	10.83	6,609	71,576		Jun 16 04:44 PM
Dolan Oliver	Officer	Jun 16 '26	Proposed Sale	10.83	3,383	36,638		Jun 16 04:44 PM
Chappell Todd	Officer	Jun 16 '26	Proposed Sale	10.83	3,168	34,310		Jun 16 04:42 PM
Aiyar Ram	President and CEO	May 29 '26	Sale	12.98	15,152	196,673	74,848	Jun 02 07:00 AM
FORMELA JEAN FRANCOIS	Director	May 28 '26	Sale	13.95	2,860	39,897	194,655	Jun 01 05:35 PM
Aiyar Ram	Officer	May 29 '26	Proposed Sale	12.98	15,152	196,676		May 29 03:09 PM
Lynx1 Capital Management LP	10% Owner	Mar 31 '26	Buy	10.60	520	5,512	1,538,296	Apr 02 12:00 PM
Yang Rick	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
SANDELL SCOTT D	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
New Enterprise Associates 17,	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
Chang Carmen	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
BASKETT FOREST	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
Mathers Edward T	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
Makhzoumi Mohamad	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
Walker Paul Edward	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM
Florence Anthony A. Jr.	10% Owner	Mar 10 '26	Buy	11.11	207,100	2,300,881	1,297,893	Mar 12 08:15 PM

TCRX Tscan Therapeutics Inc daily Stock Chart

Peers: ANVS EXOZ FBIO ICCC MCRB PLRX PMVP QTTB RLYB XBIT

| Held by: VTI VXF IWC

Index	-
Market Cap	70.58M
Enterprise Value	35.06M
Income	-124.31M
Sales	9.14M
Book/sh	1.61
Cash/sh	1.96
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	142
IPO	Jul 16, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	7.72
P/B	0.67
P/C	0.55
P/FCF	-
EV/EBITDA	-
EV/Sales	3.84
Quick Ratio	6.65
Current Ratio	6.65
Debt/Eq	0.95
LT Debt/Eq	0.88
Option/Short	No / Yes

EPS (ttm)	-0.96
EPS next Y	-0.97
EPS next Q	-0.25
EPS this Y	-2.91%
EPS next Y	5.97%
EPS next 5Y	5.09%
EPS past 3/5Y	28.66% 2.08%
Sales past 3/5Y	-8.63% 56.92%
EPS Y/Y TTM	12.20%
Sales Y/Y TTM	106.65%
EPS Q/Q	16.19%
Sales Q/Q	-54.77%
Earnings	May 06 BMO
EPS/Sales Surpr.	-8.64% -60.72%

Insider Own	14.15%
Insider Trans	0.00%
Inst Own	47.86%
Inst Trans	1.88%
ROA	-46.50%
ROE	-80.95%
ROIC	-68.29%
Gross Margin	68.48%
Oper. Margin	-1408.73%
Profit Margin	-1360.61%
SMA20	9.62%
SMA50	3.97%
SMA200	-10.61%
Trades

Shs Outstand	65.35M
Shs Float	56.10M
Short Float	1.26%
Short Ratio	0.78
Short Interest	0.71M
52W High	2.57 -57.98%
52W Low	0.83 30.89%
Volatility	13.55% 10.48%
ATR (14)	0.10
RSI (14)	53.99
Beta	1.04
Rel Volume	1.22
Avg Volume	902.48K
Volume	328,574

Perf Week	2.86%
Perf Month	17.58%
Perf Quarter	2.86%
Perf Half Y	-8.47%
Perf YTD	8.00%
Perf Year	-40.33%
Perf 3Y	-51.35%
Perf 5Y	-
Perf 10Y	-
Recom	1.33
Target Price	6.00
Prev Close	1.09
Price	1.08
Change	-0.92%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-16-24	Initiated	BTIG Research	Buy	$12
May-13-24	Initiated	Needham	Buy	$11
Jun-22-23	Initiated	Wedbush	Outperform	$8

Jun-24-26 07:00AM	TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference (GlobeNewswire)
Jun-22-26 07:00AM	TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation (GlobeNewswire) -5.97%
Jun-03-26 09:19AM	Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies (Business Wire)
May-06-26 07:00AM	TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-27-26 04:30PM	TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting (GlobeNewswire)
07:00AM	Loading…
Apr-08-26 07:00AM	TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-04-26 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-26 07:00AM	TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 (GlobeNewswire)
Feb-25-26 12:15PM	Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates (Zacks) +5.71%
07:00AM	TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-12-26 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-11-26 07:25AM	Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains? (Zacks)
Feb-06-26 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +13.14%
Dec-19-25 07:55AM	Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines (PR Newswire)
05:30PM	Loading…
Dec-06-25 05:30PM	TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Dec-04-25 12:20PM	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (PR Newswire) +6.86%
Dec-03-25 04:05PM	TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Future Market Opportunities (GlobeNewswire) +7.12%
Nov-12-25 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-10-25 05:10PM	Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +11.93%
Nov-06-25 09:15AM	Novavax (NVAX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-05-25 08:20AM	Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Nov-03-25 06:30AM	TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 (GlobeNewswire) -36.08%
Oct-30-25 09:15AM	Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-16-25 07:30AM	2 Overlooked Stocks to Snap Up in 2025 (Barchart) +11.21%
Sep-17-25 07:00AM	TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025 (GlobeNewswire) -6.98%
Sep-03-25 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.86%
Aug-12-25 03:00PM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-25 09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-06-25 05:55PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-04-25 08:25AM	Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.56%
May-28-25 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-25 09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
May-06-25 08:20AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -9.33%
07:00AM	TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-28-25 04:53PM	TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting (GlobeNewswire)
Mar-31-25 07:00AM	TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-25 07:00AM	TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access (GlobeNewswire)
Mar-05-25 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-25 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) +5.76%
Feb-18-25 07:00AM	TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference (GlobeNewswire)
Jan-10-25 09:35AM	Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks (Zacks)
Dec-26-24 07:00AM	TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium (GlobeNewswire) +6.87%
Dec-23-24 07:00AM	TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank (GlobeNewswire)
Dec-09-24 05:45PM	TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) -28.23%
Dec-05-24 08:00AM	TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years (GlobeNewswire) -5.39%
Dec-02-24 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Heme Development Strategy (GlobeNewswire)
Nov-12-24 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:43AM	TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? (Zacks)
Nov-05-24 09:15AM	TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Oct-04-24 09:05AM	TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting (GlobeNewswire)
Aug-29-24 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-14-24 07:00AM	TScan Therapeutics Announces Updates to its Board of Directors (GlobeNewswire) -6.67%
May-30-24 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-24 07:00AM	TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies (GlobeNewswire) -6.41%
May-28-24 01:24PM	Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults (PR Newswire)
May-13-24 01:53PM	TCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:09AM	Janney Starts TScan Therapeutics With Buy Rating, $11 Price Target (MT Newswires)
07:00AM	TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-24 07:00AM	TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors (GlobeNewswire)
May-01-24 10:01AM	TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +11.66%
Apr-24-24 04:05PM	TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
11:03AM	TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Apr-22-24 05:01PM	TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting (GlobeNewswire)
Apr-19-24 10:05AM	TScan Therapeutics Announces Closing of Upsized Public Offering (GlobeNewswire)
Apr-17-24 12:30AM	TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering (GlobeNewswire) -5.33%
Apr-16-24 04:25PM	TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering (GlobeNewswire) -7.28%
04:01PM	TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities (GlobeNewswire)
Apr-08-24 08:00AM	TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer (GlobeNewswire)
Apr-02-24 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -10.11%
Mar-17-24 02:58PM	Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With (InvestorPlace)
Mar-07-24 01:44PM	TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline (GuruFocus.com)
Mar-06-24 01:51PM	TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 07:00AM	TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-26-24 07:00AM	TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-19-24 05:49AM	TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar? (Zacks)
Feb-14-24 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-06-24 07:00AM	TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development (GlobeNewswire) +6.67%
Jan-29-24 07:00AM	TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer (GlobeNewswire)
Jan-18-24 07:00AM	TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire) -9.62%
Jan-04-24 07:00AM	TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress (GlobeNewswire)
Dec-09-23 12:00PM	TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Dec-07-23 07:00AM	TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations (GlobeNewswire)
Dec-06-23 08:50AM	Recent Price Trend in TScan Therapeutics, Inc. (TCRX) is Your Friend, Here's Why (Zacks)
Dec-04-23 04:05PM	TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition (GlobeNewswire) -5.56% +10.46%
07:00AM	TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer (GlobeNewswire)
Dec-01-23 09:55AM	Does TScan Therapeutics, Inc. (TCRX) Have the Potential to Rally 62.33% as Wall Street Analysts Expect? (Zacks)
Nov-30-23 07:00AM	TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years (GlobeNewswire) +12.98%
Nov-27-23 12:00PM	TScan Therapeutics, Inc. (TCRX) is a Great Momentum Stock: Should You Buy? (Zacks)
Nov-20-23 08:50AM	TScan Therapeutics, Inc. (TCRX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) -13.83%

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Waltham, MA.

CEO & DirectorDr. Gavin MacBeath Ph.D.

CFOMr. Jason A. Amello CPA

M.P.H.Dr. Chrystal U. Louis M.D.

Co-Founder & Chairman of Scientific Advisory BoardDr. Stephen J. Elledge Ph.D.

Co-Founder & Member of Advisory BoardMr. Tomasz Kula Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynx1 Capital Management LP	10% Owner	Dec 19 '25	Buy	0.90	80,069	71,974	7,937,416	Dec 23 06:17 PM
Lynx1 Capital Management LP	10% Owner	Dec 22 '25	Buy	0.90	75,500	67,950	8,012,916	Dec 23 06:17 PM
Lynx1 Capital Management LP	10% Owner	Dec 23 '25	Buy	0.90	6,232	5,602	8,019,148	Dec 23 06:17 PM

CGEM Cullinan Therapeutics Inc daily Stock Chart

Peers: IDYA RCUS TNGX CGON NUVL KYMR RYTM BMRN INCY KRYS

| Held by: XBI VTI IWM IWN VXF IBB FESM SCHA VTWO IWC

Index	RUT
Market Cap	1.09B
Enterprise Value	738.92M
Income	-221.04M
Sales	0.00M
Book/sh	5.91
Cash/sh	5.73
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	109
IPO	Jan 08, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.00
P/C	3.09
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.28
Current Ratio	10.28
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-3.71
EPS next Y	-2.41
EPS next Q	-0.80
EPS this Y	9.68%
EPS next Y	20.51%
EPS next 5Y	3.86%
EPS past 3/5Y	- -25.62%
Sales past 3/5Y	- -
EPS Y/Y TTM	-19.99%
Sales Y/Y TTM	-
EPS Q/Q	1.15%
Sales Q/Q	-
Earnings	May 07 BMO
EPS/Sales Surpr.	10.28% -

Insider Own	25.37%
Insider Trans	-0.63%
Inst Own	82.85%
Inst Trans	3.47%
ROA	-44.99%
ROE	-48.16%
ROIC	-60.09%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	4.16%
SMA50	13.48%
SMA200	44.26%
Trades

Shs Outstand	61.45M
Shs Float	46.23M
Short Float	22.92%
Short Ratio	9.77
Short Interest	10.60M
52W High	19.43 -8.85%
52W Low	5.68 211.80%
Volatility	5.00% 7.67%
ATR (14)	1.08
RSI (14)	58.30
Beta	0.00
Rel Volume	0.55
Avg Volume	1.09M
Volume	176,735

Perf Week	-0.56%
Perf Month	46.97%
Perf Quarter	21.80%
Perf Half Y	58.98%
Perf YTD	71.11%
Perf Year	130.00%
Perf 3Y	53.73%
Perf 5Y	-40.27%
Perf 10Y	-
Recom	1.00
Target Price	32.75
Prev Close	18.13
Price	17.71
Change	-2.32%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-17-26	Initiated	Citigroup	Buy	$33
Feb-02-26	Initiated	Guggenheim	Buy	$30
Aug-21-25	Resumed	H.C. Wainwright	Buy	$24
Jun-11-25	Resumed	Stifel	Buy	$22
Oct-24-24	Initiated	UBS	Buy	$30
May-01-24	Initiated	Stifel	Buy	$40
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform	$30
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy	$20
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40
Feb-02-21	Initiated	SVB Leerink	Outperform	$52
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight	$38
Feb-02-21	Initiated	Evercore ISI	Outperform	$55
Feb-01-21	Initiated	H.C. Wainwright	Buy	$47

Show Previous Ratings

Jul-02-26 06:40PM	VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone (Exec Edge)
Jun-22-26 11:40AM	Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing (Exec Edge) +15.10%
Jun-10-26 07:30AM	Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases (GlobeNewswire) -8.57%
Jun-06-26 05:15AM	Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress (GlobeNewswire)
May-26-26 07:00AM	Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager (GlobeNewswire) +11.71%
07:00AM	Loading…
May-19-26 07:00AM	Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire)
May-18-26 05:00PM	Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress (GlobeNewswire) -5.47%
08:34AM	The Biology Came First. (Business Wire)
May-07-26 07:11AM	Cullinan Therapeutics: Q1 Earnings Snapshot (Associated Press)
07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results (GlobeNewswire)
Mar-10-26 07:23AM	Cullinan Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-08-26 12:03AM	Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference (MarketBeat)
Feb-24-26 07:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-19-26 08:12PM	Cullinan Therapeutics Touts 2026 Defining Year as T-Cell Engager, Zipalertinib Catalysts Near (MarketBeat) +11.58%
07:17AM	Loading…
07:17AM	TheStreet Pro Analysts Say, Its a Stock Pickers Market Here Are 4 to Consider (TipRanks)
Feb-18-26 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-13-26 02:09AM	Cullinan Therapeutics Tees Up Catalyst-Heavy 2026 With Q2 CLN-978 Data and AML Fast Track Momentum (MarketBeat)
Feb-05-26 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-28-26 09:40AM	Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? (Zacks)
Jan-23-26 08:55AM	Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength (Zacks)
Jan-09-26 07:15AM	Cullinan Therapeutics provides corporate update, anticipated 2026 milestones (TipRanks)
Jan-08-26 07:00AM	Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones (GlobeNewswire)
Dec-15-25 11:10PM	Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates (Insider Monkey) -9.23% -5.55%
Dec-08-25 10:31AM	Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting (GlobeNewswire) +17.47%
Dec-01-25 07:00AM	Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire) -5.45%
Nov-10-25 07:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting (GlobeNewswire)
Nov-06-25 07:38AM	Cullinan Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 09:11AM	Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting (GlobeNewswire) -9.82%
11:01AM	Loading…
Oct-25-25 11:01AM	Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025 (GlobeNewswire)
Sep-23-25 10:23AM	BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy? (Zacks)
Sep-12-25 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum (GlobeNewswire)
Aug-21-25 04:05PM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.78%
Aug-07-25 07:15AM	Cullinan Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -10.79%
07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 11:40PM	Cullinan Therapeutics to Present Updated Zipalertinib Data at IASLC 2025 World Conference on Lung Cancer (Insider Monkey)
Jul-22-25 07:00AM	Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer (PR Newswire) +7.85%
Jul-14-25 08:30AM	Disc Medicine Appoints Nadim Ahmed to its Board of Directors (GlobeNewswire)
Jun-05-25 07:31AM	Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal (BioPharma Dive)
Jun-04-25 04:02PM	Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases (GlobeNewswire)
Jun-01-25 08:21AM	Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology (PR Newswire)
May-29-25 07:00AM	Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference (GlobeNewswire) +10.71%
May-22-25 05:15PM	Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 (GlobeNewswire)
May-08-25 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 09:55AM	Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know (Zacks)
Apr-29-25 07:00AM	Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sj gren's Disease in the United States (GlobeNewswire)
Apr-23-25 10:14AM	Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 (GlobeNewswire)
Apr-16-25 07:00AM	Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis (GlobeNewswire)
Apr-08-25 10:42AM	Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data (Seeking Alpha)
Feb-27-25 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-24-25 07:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-25 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-28-25 07:00PM	Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy (PR Newswire) +7.66%
Nov-14-24 10:01AM	Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 (GlobeNewswire)
Nov-07-24 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire) -5.46%
Nov-05-24 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-04-24 07:00AM	Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 (GlobeNewswire)
Oct-16-24 07:00AM	Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus (GlobeNewswire) +8.44%
Sep-17-24 07:00AM	Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus (GlobeNewswire)
Sep-16-24 07:00AM	Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus (GlobeNewswire) -5.68%
Sep-14-24 04:15AM	Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-03-24 06:26AM	Cullinan Therapeutics announces success for zipalertinib as combo therapy (Clinical Trials Arena)
Jun-01-24 07:00AM	Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib (GlobeNewswire)
May-24-24 08:00AM	Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire) +6.53%
May-23-24 05:04PM	Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 (GlobeNewswire)
May-16-24 12:03PM	HC Wainwright Adjusts Price Target on Cullinan Oncology to $28 From $29, Maintains Buy Rating (MT Newswires) -10.89%
May-15-24 10:54PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 03:09AM	Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ... (GuruFocus.com)
May-01-24 07:05AM	Stifel Initiates Cullinan Oncology With Buy Rating, $40 Price Target (MT Newswires)
Apr-29-24 07:00AM	Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer (GlobeNewswire) +7.19%
Apr-24-24 04:29PM	Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? (Benzinga) +13.32%
10:09AM	Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024 (GlobeNewswire)
Apr-16-24 03:32PM	Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity (Benzinga)
07:00AM	Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases (GlobeNewswire)
06:59AM	Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement (GlobeNewswire)
04:48AM	Cullinan changes name, pivots to autoimmune disease (BioPharma Dive)
Mar-16-24 05:31AM	Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
Mar-14-24 12:53PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-01-24 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Feb-27-24 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-02-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-30-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-24-24 07:02PM	Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares (GuruFocus.com)
Dec-18-23 04:53PM	Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.80%
Dec-14-23 04:30PM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines (GlobeNewswire)
Nov-08-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 12:01PM	Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023 (GlobeNewswire) +5.53%
Oct-30-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-06-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 07:00AM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (GlobeNewswire)
Aug-03-23 04:15PM	REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations (PR Newswire)
Jul-31-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-09-23 04:07PM	Why Shares of Cullinan Oncology Jumped This Week (Motley Fool)

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

PresidentMr. Nadim Ahmed M.S.

Chief Financial OfficerMs. Mary Kay Fenton CPA

M.D.Dr. Jeffrey Jones M.B.A.

Co-FounderDr. Patrick A. Baeuerle Ph.D.

Chief Scientific OfficerDr. Jennifer Michaelson Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Michaelson Jennifer	Chief Scientific Officer	Jul 06 '26	Option Exercise	4.30	4,000	17,200	170,844	Jul 07 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Jul 06 '26	Sale	17.82	8,000	142,560	162,844	Jul 07 05:00 PM
JENNIFER MICHAELSON	Officer	Jul 06 '26	Proposed Sale	17.63	8,000	141,040		Jul 06 04:25 PM
Michaelson Jennifer	Chief Scientific Officer	May 05 '26	Option Exercise	4.30	4,000	17,200	174,844	May 06 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	May 05 '26	Sale	14.62	8,000	116,996	166,844	May 06 05:00 PM
JENNIFER MICHAELSON	Officer	May 05 '26	Proposed Sale	15.34	8,000	122,720		May 05 04:34 PM
Michaelson Jennifer	Chief Scientific Officer	Mar 05 '26	Option Exercise	4.30	4,000	17,200	178,844	Mar 09 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Mar 05 '26	Sale	15.68	8,000	125,440	170,844	Mar 09 05:00 PM
JENNIFER MICHAELSON	Officer	Mar 05 '26	Proposed Sale	16.30	8,000	130,400		Mar 05 04:31 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 25 '26	Sale	14.14	1,780	25,169	174,844	Feb 26 05:05 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 24 '26	Sale	14.47	3,601	52,106	176,624	Feb 25 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 23 '26	Sale	13.99	1,752	24,510	180,225	Feb 25 05:00 PM
AHMED NADIM	President and CEO	Feb 24 '26	Sale	14.47	13,515	195,562	390,803	Feb 25 05:00 PM
Jones Jeffrey Alan	Chief Medical Officer	Feb 24 '26	Sale	14.47	4,582	66,302	159,968	Feb 25 05:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Feb 24 '26	Sale	14.47	3,601	52,106	128,089	Feb 25 05:00 PM
JENNIFER MICHAELSON	Officer	Feb 25 '26	Proposed Sale	14.27	1,780	25,401		Feb 25 04:33 PM
Jones Jeffrey Alan	Chief Medical Officer	Feb 20 '26	Sale	13.62	4,982	67,855	164,550	Feb 23 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 20 '26	Option Exercise	4.30	8,000	34,400	189,977	Feb 23 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 20 '26	Sale	14.08	11,742	165,366	181,977	Feb 23 05:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Feb 20 '26	Sale	13.62	3,742	50,966	131,690	Feb 23 05:00 PM
AHMED NADIM	President and CEO	Feb 20 '26	Sale	13.62	16,381	223,109	404,318	Feb 23 05:00 PM
Fenton Mary Kay	Chief Financial Officer	Feb 20 '26	Sale	13.62	4,398	59,901	126,380	Feb 23 05:00 PM
JENNIFER MICHAELSON	Officer	Feb 23 '26	Proposed Sale	13.65	1,752	23,915		Feb 23 04:31 PM
JENNIFER MICHAELSON	Officer	Feb 20 '26	Proposed Sale	13.88	8,000	111,040		Feb 20 04:27 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 12 '26	Sale	12.03	416	5,004	128,219	Feb 13 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Jan 22 '26	Sale	12.30	4,000	49,200	128,635	Jan 23 05:00 PM
JENNIFER MICHAELSON	Officer	Jan 22 '26	Proposed Sale	11.60	4,000	46,400		Jan 22 04:33 PM
AHMED NADIM	President and CEO	Dec 23 '25	Sale	10.01	9,922	99,319	420,699	Dec 29 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 19 '25	Sale	10.01	1,345	13,463	132,635	Dec 22 05:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Dec 18 '25	Sale	9.67	3,480	33,652	135,432	Dec 19 05:00 PM
Jones Jeffrey Alan	Chief Medical Officer	Dec 18 '25	Sale	9.67	4,632	44,791	169,532	Dec 19 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 18 '25	Sale	9.67	2,898	28,024	133,980	Dec 19 05:00 PM
JENNIFER MICHAELSON	Officer	Dec 19 '25	Proposed Sale	9.98	1,345	13,423		Dec 19 04:23 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 12 '25	Sale	12.38	2,148	26,592	137,873	Dec 16 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 15 '25	Sale	11.90	995	11,840	136,878	Dec 16 05:00 PM
JENNIFER MICHAELSON	Officer	Dec 15 '25	Proposed Sale	11.92	995	11,860		Dec 15 04:16 PM
Michaelson Jennifer	Chief Scientific Officer	Nov 24 '25	Sale	12.30	4,000	49,200	138,004	Nov 25 05:00 PM
JENNIFER MICHAELSON	Officer	Nov 24 '25	Proposed Sale	9.47	4,000	37,880		Nov 24 04:28 PM
Lynx1 Capital Management LP	10% Owner	Oct 28 '25	Buy	8.40	165,667	1,391,686	8,963,500	Oct 30 05:13 PM
Lynx1 Capital Management LP	10% Owner	Oct 16 '25	Buy	8.86	150,000	1,328,250	8,765,616	Oct 21 07:00 PM
Lynx1 Capital Management LP	10% Owner	Oct 15 '25	Buy	7.94	51,500	409,049	8,615,616	Oct 21 07:00 PM
Lynx1 Capital Management LP	10% Owner	Oct 17 '25	Buy	7.84	32,217	252,565	8,797,833	Oct 21 07:00 PM
Lynx1 Capital Management LP	10% Owner	Oct 14 '25	Buy	7.59	15,032	114,048	8,564,116	Oct 21 07:00 PM
Lynx1 Capital Management LP	10% Owner	Oct 09 '25	Buy	6.70	626,043	4,191,859	8,271,786	Oct 10 06:58 PM
Lynx1 Capital Management LP	10% Owner	Oct 08 '25	Buy	6.46	556,300	3,593,698	7,645,743	Oct 10 06:58 PM
Lynx1 Capital Management LP	10% Owner	Oct 10 '25	Buy	7.36	277,298	2,041,385	8,549,084	Oct 10 06:58 PM

NEUP Neuphoria Therapeutics Inc daily Stock Chart

Peers: APRE BCDA BIVI CALC CVM GOVX KAPA KPRX AIM JAGX

| Held by: PSIL VTI VXF

Index	-
Market Cap	18.47M
Enterprise Value	-0.94M
Income	-
Sales	-
Book/sh	5.47
Cash/sh	3.60
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	Dec 16, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.63
P/C	0.95
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	14.31
Current Ratio	14.31
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-2.43
EPS next Q	-0.56
EPS this Y	-1669.57%
EPS next Y	40.29%
EPS next 5Y	-
EPS past 3/5Y	-17.62% -20.01%
Sales past 3/5Y	334.17% 246.61%
EPS Y/Y TTM	-15957.73%
Sales Y/Y TTM	-
EPS Q/Q	92.44%
Sales Q/Q	-100.00%
Earnings	Jun 03
EPS/Sales Surpr.	0.00% -

Insider Own	9.05%
Insider Trans	0.00%
Inst Own	34.56%
Inst Trans	6.11%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-15.02%
SMA50	-26.17%
SMA200	-37.78%
Trades

Shs Outstand	-
Shs Float	4.92M
Short Float	0.32%
Short Ratio	0.24
Short Interest	0.02M
52W High	21.40 -84.02%
52W Low	3.19 7.21%
Volatility	6.91% 8.32%
ATR (14)	0.30
RSI (14)	30.34
Beta	0.74
Rel Volume	0.63
Avg Volume	64.65K
Volume	12,140

Perf Week	-0.58%
Perf Month	-22.62%
Perf Quarter	-28.45%
Perf Half Y	-15.97%
Perf YTD	-11.86%
Perf Year	-55.53%
Perf 3Y	-88.95%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	7.00
Prev Close	3.54
Price	3.42
Change	-3.39%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-28-23	Upgrade	H.C. Wainwright	Neutral → Buy	$8
Sep-28-23	Reiterated	Maxim Group	Buy	$7 → $10
Jan-10-22	Initiated	H.C. Wainwright	Buy	$54
Jan-10-22	Initiated	Evercore ISI	Outperform	$17
Jan-10-22	Initiated	Cantor Fitzgerald	Overweight	$52
Jan-10-22	Initiated	Berenberg	Buy	$21

Jul-01-26 06:01PM	MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimers Drug Trial Under Neuphoria Partnership (Stocktwits) -18.76%
Jun-26-26 04:15PM	Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc (GlobeNewswire) +5.06%
09:45AM	Scancell confirms advanced talks over reverse merger with Neuphoria (Proactive)
Dec-08-25 08:00AM	Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees (GlobeNewswire) +6.32%
Dec-04-25 08:00AM	Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium (GlobeNewswire)
08:00AM	Loading…
Dec-01-25 08:00AM	Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions (GlobeNewswire)
Nov-24-25 08:00AM	Neuphoria Therapeutics Inc. Sends Letter to Stockholders (GlobeNewswire)
Nov-11-25 07:00AM	Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value (GlobeNewswire)
Oct-27-25 04:29PM	Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process (GlobeNewswire) -27.40%
Oct-22-25 12:53PM	Neuphoria scraps social anxiety hopeful after Phase III miss (Clinical Trials Arena) -11.34%
Oct-20-25 04:15PM	Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder (GlobeNewswire) -68.51%
Sep-29-25 04:54PM	Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates (GlobeNewswire)
Sep-04-25 07:00AM	Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD) (GlobeNewswire) -8.31%
Aug-28-25 04:05PM	Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +19.47% -7.21%
May-27-25 04:10PM	Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting (GlobeNewswire)
04:22PM	Loading…
May-20-25 04:22PM	Neuphoria Provides First Quarter 2025 Business Updates (GlobeNewswire) +9.86%
Apr-15-25 08:00AM	Neuphoria Provides a Review of 2024 and Highlights 2025 Plans (GlobeNewswire)
Mar-03-25 07:30AM	Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025 (GlobeNewswire) -5.19%
Feb-12-25 07:00AM	Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck (GlobeNewswire)
Jan-25-25 05:13PM	Why Neuphoria Therapeutics Inc. (NEUP) Surged on Friday (Insider Monkey)
Dec-24-24 05:49PM	Bionomics Strategic Shift with Neuphoria Redomiciliation (TipRanks) +118.29% -32.88%
Dec-16-24 04:05PM	Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation (GlobeNewswire) -11.76%
Dec-12-24 04:05PM	Results of Scheme Meeting (GlobeNewswire) +5.29% +6.88%
Dec-09-24 08:00AM	Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence (GlobeNewswire)
Dec-03-24 04:05PM	Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting (GlobeNewswire) -6.56%
Dec-02-24 05:01PM	Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States (GlobeNewswire)
Nov-08-24 04:15PM	Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement (GlobeNewswire) +6.53% -9.12%
Nov-07-24 08:00AM	Bionomics to Present at the 2024 CNS Summit (GlobeNewswire) +36.25%
Nov-04-24 04:15PM	Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program (GlobeNewswire) +157.79%
Oct-23-24 06:00AM	Bionomics to Present at the ThinkEquity Conference (GlobeNewswire)
08:00AM	Loading…
Oct-14-24 08:00AM	Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (GlobeNewswire) -6.82%
Oct-08-24 08:50AM	Bionomics CEO believes company has significant, unrealized value (TipRanks)
Oct-07-24 08:00AM	Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision (GlobeNewswire)
Oct-01-24 06:30AM	Bionomics Limited announces intention to re-domicile to the United States (GlobeNewswire) -11.20%
Sep-03-24 06:30AM	Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Jul-31-24 06:30AM	Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder (GlobeNewswire) -9.78%
Jul-29-24 04:30PM	Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024 (GlobeNewswire) +24.01%
Jul-18-24 06:30AM	Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder (GlobeNewswire)
May-31-24 08:00AM	Bionomics Limited Announces Private Placement of up to $70.0 Million (GlobeNewswire) -14.97%
May-20-24 06:30AM	Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting (GlobeNewswire)
Mar-21-24 06:00AM	Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (GlobeNewswire)
Feb-22-24 04:30PM	Bionomics to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire) -8.00%
Feb-05-24 03:11AM	10 Best Australian Stocks To Buy (Insider Monkey)
Feb-04-24 11:01AM	7 Strong Buy Stocks Under $20: February 2024 (InvestorPlace)
Jan-22-24 06:00AM	Bionomics Provides a Review of 2023 and of 2024 Plans (GlobeNewswire)
Jan-05-24 06:00AM	Bionomics to Present at Biotech Showcase 2024 (GlobeNewswire)
Dec-06-23 08:00AM	Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting (GlobeNewswire) +5.08%
Oct-30-23 02:02PM	12 Best Stocks For Day Trading (Insider Monkey)
Oct-16-23 08:00AM	Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder (GlobeNewswire) +14.18%
Sep-29-23 08:51AM	Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244% (Zacks) -19.88%
12:13AM	Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) (PR Newswire)
Sep-28-23 08:03AM	Why Is Bionomics (BNOX) Stock Up 347% Today? (InvestorPlace) +242.13%
07:09AM	Bionomics' midphase PTSD trial hits primary endpoint, briefly tripling its battered share price (FierceBiotech.com)
06:00AM	Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) (GlobeNewswire)
Sep-14-23 06:00AM	Bionomics Announces Update on the 7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD (GlobeNewswire) -25.14%
Aug-24-23 11:50AM	Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate (Zacks) +7.91%
Aug-23-23 06:00AM	Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210 (GlobeNewswire) +15.83%
Jul-31-23 06:00AM	Quarterly Activities and Cashflow Report (GlobeNewswire) -14.14%
Jul-25-23 06:00AM	Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX) (GlobeNewswire) -15.93%
Jul-15-23 08:27PM	Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jul-03-23 06:00AM	Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth (GlobeNewswire) +5.95%
Jun-15-23 08:00AM	Bionomics to Present at Upcoming June Investor Conferences (GlobeNewswire)
May-30-23 06:00AM	Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (GlobeNewswire) -5.62%
Apr-28-23 06:00AM	Quarterly Activities and Cashflow Report (GlobeNewswire)
Apr-27-23 06:00AM	Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) (GlobeNewswire)
Mar-09-23 10:54AM	Bionomics Reveals Detailed Data From Its Flunked Anxiety Trial, Shows Reductions In Anxiety Across Multiple Phases (Benzinga) -26.24%
Mar-08-23 07:00PM	Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD) (GlobeNewswire) +7.39%
Mar-03-23 09:55AM	Bears are Losing Control Over Bionomics Limited Unsponsored ADR (BNOX), Here's Why It's a 'Buy' Now (Zacks)
Feb-24-23 03:05PM	Bionomics First Half 2023 Earnings: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022) (Simply Wall St.) +19.03%
Feb-23-23 06:00AM	Bionomics Half-Year Report (GlobeNewswire) +9.47%
Feb-05-23 07:02PM	Will Bionomics (ASX:BNO) Spend Its Cash Wisely? (Simply Wall St.)
Jan-30-23 06:23PM	Quarterly Activities and Cashflow Report (GlobeNewswire) -6.20%
Dec-19-22 03:29PM	All Focus Shifts To Bionomics' PTSD Study After Anxiety Trial Disappoints (Benzinga) -13.38%
09:30AM	Bionomics' Social Anxiety Disorder Study Fails To Meet Primary Endpoint (Benzinga)
Dec-18-22 07:34PM	Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder (GlobeNewswire)
Dec-15-22 06:35PM	Bionomics appoints Spyridon Spyros Papapetropoulos as President and Chief Executive Officer (GlobeNewswire)
Dec-02-22 06:00AM	Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting (GlobeNewswire)
Nov-21-22 06:13PM	Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States (GlobeNewswire)
Nov-16-22 06:36PM	Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States (GlobeNewswire) -17.41%
Nov-02-22 06:00AM	Bionomics Limited to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-25-22 06:00AM	Quarterly Activities Report for September 2022 (GlobeNewswire)
Oct-18-22 06:00AM	Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million (GlobeNewswire)
Oct-07-22 04:39PM	Bionomics (ASX:BNO) adds AU$20m to market cap in the past 7 days, though investors from five years ago are still down 84% (Simply Wall St.)
Oct-04-22 06:00AM	Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference (GlobeNewswire)
Sep-21-22 06:00AM	Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder (GlobeNewswire)
Sep-15-22 09:55AM	Can Bionomics Limited Unsponsored ADR (BNOX) Climb 329% to Reach the Level Wall Street Analysts Expect? (Zacks)
Aug-31-22 06:00AM	Bionomics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-30-22 09:55AM	Does Bionomics Limited Unsponsored ADR (BNOX) Have the Potential to Rally 329% as Wall Street Analysts Expect? (Zacks)
Aug-27-22 06:26PM	We're Keeping An Eye On Bionomics' (ASX:BNO) Cash Burn Rate (Simply Wall St.)
Aug-25-22 06:00AM	Bionomics reports Full Year Financial Results (GlobeNewswire) +7.42%
Aug-08-22 06:00AM	Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M (GlobeNewswire)
Jul-29-22 06:00AM	Quarterly Activities Report for June 2022 (GlobeNewswire)
Jul-08-22 06:00AM	Bionomics to Participate in William Blairs Biotech Focus Conference 2022 (GlobeNewswire) +8.82%
Jun-27-22 06:00AM	Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference (GlobeNewswire)
Jun-24-22 07:44AM	Fewer Investors Than Expected Jumping On Maxim Power Corp. (TSE:MXG) (Simply Wall St.)
Jun-13-22 04:30PM	Bionomics Investor Webinar (GlobeNewswire) -14.02% +5.62%
May-16-22 06:00AM	Bionomics Limited to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-10-22 08:00AM	Novamind to Host Bionomics PREVAIL Trial for Acute Treatment of Social Anxiety Disorder (ACCESSWIRE)
Feb-23-22 09:00PM	Bionomics' Half-Year Report (GlobeNewswire)
Jan-14-22 07:06AM	Bionomics Limited (Nasdaq: BNOX, ASX: BNO) to Ring the Nasdaq Stock Market Closing Bell on Friday January 14, 2022 (PR Newswire)

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Ph.D.Dr. Spyridon Papapetropoulos M.D.

M.B.A.Mr. Timothy M. Cunningham CPA

Senior Vice President of Clinical DevelopmentMs. Elizabeth Doolin M.Sc.

Senior Vice President of Business OperationsDr. Julie Kerner Ph.D.

F.C.A.Mr. Adrian Hinton BEC

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynx1 Capital Management LP	10% Owner	Oct 21 '25	Buy	5.14	639,110	3,283,108	875,328	Oct 23 07:49 PM

PASG

Passage Bio Inc

KRRO

Korro Bio Inc

TCRX

Tscan Therapeutics Inc

CGEM

Cullinan Therapeutics Inc

NEUP

Neuphoria Therapeutics Inc

Upgrade your Finviz experience